Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 166

1.

Influence of PSA, PSA velocity and PSA doubling time on contrast-enhanced 18F-choline PET/CT detection rate in patients with rising PSA after radical prostatectomy.

Schillaci O, Calabria F, Tavolozza M, Caracciolo CR, Finazzi Agrò E, Miano R, Orlacchio A, Danieli R, Simonetti G.

Eur J Nucl Med Mol Imaging. 2012 Apr;39(4):589-96. doi: 10.1007/s00259-011-2030-7. Epub 2012 Jan 10.

PMID:
22231016
2.

PET/CT with (18)F-choline after radical prostatectomy in patients with PSA ≤2 ng/ml. Can PSA velocity and PSA doubling time help in patient selection?

Chiaravalloti A, Di Biagio D, Tavolozza M, Calabria F, Schillaci O.

Eur J Nucl Med Mol Imaging. 2016 Jul;43(8):1418-24. doi: 10.1007/s00259-015-3306-0. Epub 2016 Jan 21.

PMID:
26791373
3.

Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.

Castellucci P, Fuccio C, Nanni C, Santi I, Rizzello A, Lodi F, Franceschelli A, Martorana G, Manferrari F, Fanti S.

J Nucl Med. 2009 Sep;50(9):1394-400. doi: 10.2967/jnumed.108.061507. Epub 2009 Aug 18. Erratum in: J Nucl Med. 2009 Oct;50(10):1578.

4.

Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.

Rodado-Marina S, Coronado-Poggio M, García-Vicente AM, García-Garzón JR, Alonso-Farto JC, de la Jara AC, Maldonado-Suárez A, Rodríguez-Fernández A.

BJU Int. 2015 Jun;115(6):874-83. doi: 10.1111/bju.12953. Epub 2015 Jan 21.

5.

Role of 18F-choline PET/CT in biochemically relapsed prostate cancer after radical prostatectomy: correlation with trigger PSA, PSA velocity, PSA doubling time, and metastatic distribution.

Marzola MC, Chondrogiannis S, Ferretti A, Grassetto G, Rampin L, Massaro A, Castellucci P, Picchio M, Al-Nahhas A, Colletti PM, Marcolongo A, Rubello D.

Clin Nucl Med. 2013 Jan;38(1):e26-32. doi: 10.1097/RLU.0b013e318266cc38.

PMID:
23242060
6.

Prostate-specific antigen velocity versus prostate-specific antigen doubling time for prediction of 11C choline PET/CT in prostate cancer patients with biochemical failure after radical prostatectomy.

Giovacchini G, Picchio M, Parra RG, Briganti A, Gianolli L, Montorsi F, Messa C.

Clin Nucl Med. 2012 Apr;37(4):325-31. doi: 10.1097/RLU.0b013e31823363b0.

PMID:
22391699
7.

Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy?

Castellucci P, Ceci F, Graziani T, Schiavina R, Brunocilla E, Mazzarotto R, Pettinato C, Celli M, Lodi F, Fanti S.

J Nucl Med. 2014 Sep;55(9):1424-9. doi: 10.2967/jnumed.114.138313. Epub 2014 Jun 16.

8.

(11)C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy.

Ceci F, Castellucci P, Mamede M, Schiavina R, Rubello D, Fuccio C, Ambrosini V, Boschi S, Martorana G, Fanti S.

Eur J Nucl Med Mol Imaging. 2013 Jan;40(2):149-55. doi: 10.1007/s00259-012-2272-z. Epub 2012 Nov 14.

PMID:
23151910
9.

PSA doubling time for prediction of [(11)C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy.

Giovacchini G, Picchio M, Scattoni V, Garcia Parra R, Briganti A, Gianolli L, Montorsi F, Messa C.

Eur J Nucl Med Mol Imaging. 2010 Jun;37(6):1106-16. doi: 10.1007/s00259-010-1403-7. Epub 2010 Mar 20.

PMID:
20306038
10.

Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.

Morigi JJ, Stricker PD, van Leeuwen PJ, Tang R, Ho B, Nguyen Q, Hruby G, Fogarty G, Jagavkar R, Kneebone A, Hickey A, Fanti S, Tarlinton L, Emmett L.

J Nucl Med. 2015 Aug;56(8):1185-90. doi: 10.2967/jnumed.115.160382. Epub 2015 Jun 25.

11.

11C-choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT.

Ceci F, Castellucci P, Graziani T, Schiavina R, Brunocilla E, Mazzarotto R, Ntreta M, Lodi F, Martorana G, Fanti S.

Eur J Nucl Med Mol Imaging. 2014 May;41(5):878-86. doi: 10.1007/s00259-013-2655-9. Epub 2013 Dec 18.

PMID:
24346416
12.

The role of 11C-choline PET imaging in the early detection of recurrence in surgically treated prostate cancer patients with very low PSA level <0.5 ng/mL.

Mamede M, Ceci F, Castellucci P, Schiavina R, Fuccio C, Nanni C, Brunocilla E, Fantini L, Costa S, Ferretti A, Colletti PM, Rubello D, Fanti S.

Clin Nucl Med. 2013 Sep;38(9):e342-5. doi: 10.1097/RLU.0b013e31829af913.

PMID:
23797218
13.

18F-Fluoroethylcholine PET/CT identifies lymph node metastasis in patients with prostate-specific antigen failure after radical prostatectomy but underestimates its extent.

Tilki D, Reich O, Graser A, Hacker M, Silchinger J, Becker AJ, Khoder W, Bartenstein P, Stief CG, Loidl W, Seitz M.

Eur Urol. 2013 May;63(5):792-6. doi: 10.1016/j.eururo.2012.08.003. Epub 2012 Aug 10.

PMID:
22902037
14.

Significant increase in detection of prostate cancer recurrence following radical prostatectomy with an early imaging acquisition protocol with ¹⁸F-fluorocholine positron emission tomography/computed tomography.

Simone G, Di Pierro GB, Papalia R, Sciuto R, Rea S, Ferriero M, Guaglianone S, Maini CL, Gallucci M.

World J Urol. 2015 Oct;33(10):1511-8. doi: 10.1007/s00345-015-1481-z. Epub 2015 Jan 11.

PMID:
25577130
15.

[(11)C]choline PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy.

Rinnab L, Simon J, Hautmann RE, Cronauer MV, Hohl K, Buck AK, Reske SN, Mottaghy FM.

World J Urol. 2009 Oct;27(5):619-25. doi: 10.1007/s00345-009-0371-7. Epub 2009 Feb 21.

PMID:
19234708
16.

Prostate-specific antigen kinetics parameters are predictive of positron emission tomography features worsening in patients with biochemical relapse after prostate cancer treatment with radical intent: Results from a longitudinal cohort study.

Gacci M, Cai T, Siena G, Minervini A, Torshizi MF, Bartolini M, Giannì G, Saieva C, Ceroti M, Detti B, Livi L, Pupi A, Carini M.

Scand J Urol. 2014 Jun;48(3):259-67. doi: 10.3109/21681805.2013.846936. Epub 2013 Nov 21.

PMID:
24255954
17.

Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml?

Heinisch M, Dirisamer A, Loidl W, Stoiber F, Gruy B, Haim S, Langsteger W.

Mol Imaging Biol. 2006 Jan-Feb;8(1):43-8.

PMID:
16315004
18.

Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy.

Giovacchini G, Picchio M, Coradeschi E, Bettinardi V, Gianolli L, Scattoni V, Cozzarini C, Di Muzio N, Rigatti P, Fazio F, Messa C.

Eur J Nucl Med Mol Imaging. 2010 Feb;37(2):301-9. doi: 10.1007/s00259-009-1253-3. Epub 2009 Sep 15.

PMID:
19756592
19.

Impact of total PSA, PSA doubling time and PSA velocity on detection rates of 11C-Choline positron emission tomography in recurrent prostate cancer.

Rybalov M, Breeuwsma AJ, Leliveld AM, Pruim J, Dierckx RA, de Jong IJ.

World J Urol. 2013 Apr;31(2):319-23. doi: 10.1007/s00345-012-0908-z. Epub 2012 Jul 20.

PMID:
22814886
20.

Predictive factors of [18F]-Choline PET/CT in 170 patients with increasing PSA after primary radical treatment.

Detti B, Scoccianti S, Franceschini D, Cipressi S, Cassani S, Villari D, Gacci M, Pupi A, Vaggelli L, Saieva C, Pertici M, Livi L, Ceroti M, Nicita G, Carini M, Biti G.

J Cancer Res Clin Oncol. 2013 Mar;139(3):521-8. doi: 10.1007/s00432-012-1354-4. Epub 2012 Nov 27.

PMID:
23183655

Supplemental Content

Support Center